Recent Updates
Recently added Catalysts
IONS Positive Sentiment

Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

Friday, October 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Roche, a partner of Ionis Pharmaceuticals, presented new Phase 3 data showing that sefaxersen significantly reduced proteinuria by 43.1% in adults with IgA nephropathy. This reduction was statistically significant with a P-value of less than 0.0001. The findings were shared during a late-breaking oral presentation from the ongoing IMAgINATION study.

Market Sentiment Analysis

POSITIVE FACTORS

  • Sefaxersen achieved a 43.1% reduction in proteinuria.
  • Data from the Phase 3 IMAgINATION study is promising.
  • Results were statistically significant with a P-value of less than 0.0001.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+7%
120-day peak, hindsight
Typical move
4.4%
average across 15 past catalysts
Lead asset
IONIS-FB-LRx
Phase 2 · Macular Degeneration

Full Press Release Details

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Roche announced today late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with primary IgA nephropathy (IgAN) receiving optimized standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence interval [CI]: 32.5 - 52.0, P<0.0001), relative to placebo at 37 wee

Frequently Asked Questions

What is sefaxersen?

Sefaxersen is an investigational drug for treating IgA nephropathy.

What were the results of the Phase 3 study?

The study showed a 43.1% reduction in proteinuria compared to placebo.

What is IgA nephropathy?

IgA nephropathy is a kidney disease characterized by the deposition of IgA.

What does a P-value of less than 0.0001 indicate?

It indicates that the results are statistically significant.

ShareAdd on Google
Tags: IONS Ionis Pharmaceuticals Roche sefaxersen IgA nephropathy Phase 3
Last updated: Oct 23, 2026

Biotech snapshot

Cash runway
$2055M liquidity · $0M/mo burn
Low dilution risk
Lead asset
IONIS-FB-LRxPhase 2
Macular Degeneration →

Catalyst track record

+7%
best trade around IONS's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for IONS.

See every catalyst's timing & PoA →